

Global Healthcare CEO Joins Nexsen Advisory Board

Investor Highlights:

- **Leadership from a ~\$25.7 billion global healthcare group**
Dr Tsang is CEO of IHH Healthcare North Asia, part of one of the world's largest private healthcare providers, with a market capitalisation of approximately \$25.7 billion and 190 healthcare facilities across 10 countries
- **Large-scale healthcare expertise added to Nexsen**
Appointment brings capability across hospital operations, clinical services, medical affairs, procurement, supply chain and healthcare adoption pathways
- **Strengthens market engagement and rollout**
Dr Tsang's healthcare insight and hospital network will support Nexsen's Asia-Pacific market rollout, including clinical engagement, hospital adoption planning and commercial pathway development
- **Builds on Asia-Pacific strategy**
Appointment follows Nexsen's MoU with Gleneagles Hospital Hong Kong, part of IHH Healthcare, supporting validation and potential rollout across Asia-Pacific

Nexsen Limited (ASX:NXN) ("Nexsen" or the "Company"), is pleased to announce the appointment of Dr Kenneth Tsang to the Company's Advisory Board, adding expertise from a global healthcare leader and materially strengthening the Company's ability to roll out its proprietary rapid diagnostics platform across Asia-Pacific.

Dr Tsang is a senior healthcare executive with leadership experience across one of Asia's most significant private healthcare platforms, IHH Healthcare. He currently serves as Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong, part of IHH Healthcare, one of the world's largest private healthcare providers with a market capitalisation of approximately A\$25.7 billion and a network of 190 healthcare facilities across 10 countries, including 89 hospitals.

Dr Tsang has served as CEO of Gleneagles Hospital Hong Kong since January 2021 and was appointed CEO of IHH Healthcare North Asia in April 2024. His appointment adds large-scale healthcare operating experience to Nexsen at a key stage in the Company's development, as it progresses from product development and validation towards market readiness.

Dr Tsang's experience spans hospital operations, clinical service delivery, medical affairs, quality systems, risk management, specialist clinic development, procurement and healthcare adoption pathways. This expertise is expected to support Nexsen across product rollout planning, clinical workflow integration, supply chain readiness and regional market engagement across Asia-Pacific.

The appointment follows Nexsen's recently announced MoU with Gleneagles Hospital Hong Kong, part of IHH Healthcare, supporting the validation and potential rollout of Nexsen's proprietary rapid diagnostics platform. The MoU represents Nexsen's first Asian hospital partnership and forms part of the Company's broader strategy to build clinical and commercial pathways for its rapid diagnostics platform across the region.

Dr Kenneth Tsang, commented:

"I am pleased to join Nexsen's Advisory Board at an exciting stage in the Company's development. Nexsen is addressing an important healthcare need by giving clinicians faster access to reliable diagnostic information at the point of care. I look forward to supporting the Company advance its rapid diagnostics platform."

Managing Director, Mark Muzzin, commented:

“Kenneth’s appointment brings a deep understanding of how hospitals operate, evaluate new technologies and integrate products into clinical practice. His guidance will be highly valuable as we progress our rapid diagnostics platform throughout Asia-Pacific.”

Executive Chairman, Reece O’Connell, commented:

“We are excited to welcome Dr Kenneth Tsang to Nexsen’s Advisory Board. His appointment brings real-world healthcare expertise at significant scale into the Company at an important stage of our journey. The calibre of Kenneth’s experience, leading within one of the world’s largest private healthcare groups, is a strong validation of the opportunity Nexsen is pursuing and the potential for our rapid diagnostics platform.”

-ENDS-

ASX release authorised by the Board of Directors.

For more information, please contact:

Corporate Enquiries

e: corporate@nexsen.bio

w: www.nexsen.bio

a: Suite 1005, 4 Bridge Street, Sydney NSW 2000, Australia

Company Secretary

e: NXN@reignadvisory.com

p: 61 2 9174 5388

About Nexsen Limited (ASX: NXN)

Nexsen is developing a suite of rapid point-of-care diagnostics for conditions that have traditionally depended on delayed laboratory testing. The company is focused on areas of significant unmet clinical need, where faster diagnosis can improve patient outcomes and reduce pressure on healthcare systems. Nexsen’s lead diagnostic is the GBS Rapid Sensor, a rapid point-of-care diagnostic for detecting Group B Streptococcus, addressing a critical unmet need in maternal health. The Company is also developing rapid kidney function diagnostics for Acute Kidney Injury and Chronic Kidney Disease, two conditions that affect more than 850 million people globally and remain underserved by slow, lab-based diagnostics.

With further diagnostics in development across human health, ag-tech and biosecurity, Nexsen aims to become a global leader in rapid point-of-care diagnostics, delivering on its mission to ensure every person benefits from a Nexsen test at some point in their life.

Forward Looking Statements Disclaimer

Forward looking statements are typically identified by the use of forward looking terminology such as ‘aims’, ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘intends’, ‘estimates’, ‘plans’, ‘assumes’, ‘envisages’, or the negative thereof or other words of similar meaning. Examples of such forward looking statements include, among others, statements or discussions regarding the Company’s business, financial or investment strategies, regulatory and product rollout strategies, estimates of expenditure, present or future plans or events, prospects, growth, objectives for future operations and estimates. Such forward looking statements include matters that are not historical facts and are subject to a number of risks and uncertainties, many of which are beyond the Company’s control and all of which are based on the Company’s current beliefs, intentions or expectations about future events. Such statements are, by their nature, subject to a number of known and unknown risks, uncertainties, assumptions and other important factors that could cause actual

results, performance or achievements to differ materially from any expected future results, performance or achievements expressed or implied, by the forward looking statement.

Neither the Company nor any person gives any representation, assurance or guarantee that the occurrence of the event expressed or implied in any forward looking statements in this document will actually occur and you are cautioned not to place undue reliance on such forward looking statements. Factors that might cause forward looking statements to differ materially from actual results, performance or achievements include, among other things, global economic conditions, economic conditions in jurisdictions in which the Company may operate or invest, credit markets, legislative fiscal and regulatory developments, the effects of continued volatility in markets and exchange rate fluctuations. The forward looking statements contained in this document speak only as of the date this document and each of the Company, respective directors, officers, employees, agents, representatives and/or advisers expressly disclaims any obligations or undertaking to release any update of, or revisions to, any forward looking statements in this document.